Brokers Offer Predictions for CG Oncology FY2026 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Research analysts at HC Wainwright raised their FY2026 EPS estimates for CG Oncology in a report released on Friday, November 6th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($2.94) for the year, up from their previous forecast of ($3.60). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($3.31) per share. HC Wainwright also issued estimates for CG Oncology’s Q4 2026 earnings at ($0.70) EPS, Q1 2027 earnings at ($0.85) EPS, Q3 2027 earnings at ($1.02) EPS, FY2027 earnings at ($3.61) EPS, FY2028 earnings at ($1.33) EPS and FY2030 earnings at $5.00 EPS.

Several other analysts also recently weighed in on the stock. Truist Financial boosted their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Wall Street Zen upgraded CG Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday. Royal Bank Of Canada lowered their target price on shares of CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Wedbush increased their price objective on CG Oncology from $80.00 to $84.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a research report on Thursday, October 15th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $88.11.

CG Oncology Price Performance

Shares of NASDAQ CGON opened at $74.74 on Tuesday. The business has a 50-day moving average of $68.24 and a two-hundred day moving average of $66.18. The company has a market capitalization of $6.62 billion, a price-to-earnings ratio of -27.08 and a beta of 0.35. CG Oncology has a 1 year low of $35.80 and a 1 year high of $80.97.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings results on Friday, November 6th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. The company had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $0.55 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in CG Oncology during the 2nd quarter worth approximately $444,509,000. Seven Fleet Capital Management LP raised its stake in CG Oncology by 24.5% during the second quarter. Seven Fleet Capital Management LP now owns 1,886,236 shares of the company’s stock valued at $134,017,000 after buying an additional 371,085 shares in the last quarter. Bank of America Corp DE raised its position in shares of CG Oncology by 21.8% during the 1st quarter. Bank of America Corp DE now owns 1,449,364 shares of the company’s stock valued at $98,093,000 after acquiring an additional 259,311 shares in the last quarter. EcoR1 Capital LLC lifted its position in shares of CG Oncology by 3.5% in the 1st quarter. EcoR1 Capital LLC now owns 1,102,000 shares of the company’s stock worth $74,583,000 after buying an additional 37,200 shares during the last quarter. Finally, Jefferies Financial Group Inc. lifted its holdings in CG Oncology by 8.5% in the third quarter. Jefferies Financial Group Inc. now owns 835,342 shares of the company’s stock worth $59,217,000 after acquiring an additional 65,395 shares during the last quarter. 26.56% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $62.06, for a total transaction of $62,060.00. Following the completion of the sale, the director owned 1,000 shares of the company’s stock, valued at approximately $62,060. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders sold 3,000 shares of company stock worth $209,580. 4.80% of the stock is currently owned by insiders.

CG Oncology News Summary

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $100 price target. It raised its Q4 2026 EPS estimate to a loss of $0.70 from $1.03 and its FY2026 estimate to a loss of $2.94 from $3.60, signaling a less severe expected loss near term. CG Oncology coverage
• Positive Sentiment: Wedbush raised its price target to $84 from $80 and maintained an “Outperform” rating, suggesting continued upside in the analyst’s view. Wedbush ratings
• Negative Sentiment: HC Wainwright cut its EPS forecasts for FY2027 (to a $3.61 loss from $2.83), FY2028 (to a $1.33 loss from $0.65), and FY2030 (to $5.00 profit from $6.88). These lower longer-term expectations temper the positive near-term revisions.
• Negative Sentiment: Guggenheim trimmed its target to $89 from $90, although it kept a “Buy” rating. Guggenheim ratings

CG Oncology Company Profile

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder.

Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

CG Oncology has no approved commercial products.